


RealRate

PHARMACEUTICAL 2023











PHARMACEUTICAL 2023





Amphastar Pharmaceuticals Inc. Rank 89 of 446

The relative strengths and weaknesses of Amphastar Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Amphastar Pharmaceuticals Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 107% points. The greatest weakness of Amphastar Pharmaceuticals Inc. is the variable Cost of Goods Sold, reducing the Economic Capital Ratio by 46% points.

The company's Economic Capital Ratio, given in the ranking table, is 209%, being 166% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	378,319
Cost of Goods Sold	250,127
Intangible Assets	0
Liabilities, Current	94,862
Liabilities, Non-Current	38,259
Other Assets	125,402
Other Compr. Net Income	-1,859
Other Expenses	45,008
Other Liabilities	80,208
Other Net Income	7,366
Other Revenues	498,987
Property and Equipment	238,266
Research and Development	74,771
Selling, General and Administrative Expense	45,061

Output Variable	Value in 1000 USD
Assets	741,987
Liabilities	213,329
Expenses	414,967
Revenues	498,987
Stockholders Equity	528,658
Net Income	91,386
Comprehensive Net Income	90,456
Economic Capital Ratio	209%

